Karyopharm to Participate in Baird's Biotech Discovery Series

Company Overview - Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies, particularly in oral compounds that address nuclear export dysregulation, a key mechanism in oncogenesis [3]. - The company's lead compound, XPOVIO® (selinexor), is a first-in-class oral exportin 1 (XPO1) inhibitor approved in the U.S. for three oncology indications and has received regulatory approvals in 50 ex-U.S. territories, including the EU, UK (as NEXPOVIO®), and China [3]. Upcoming Event - Karyopharm's senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on December 10, 2025, at 12:00 p.m. ET [1]. - The event will be accessible via a live webcast on the company's investor website and will be available for replay afterward [2]. Pipeline and Focus Areas - Karyopharm has a focused pipeline targeting multiple high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL) [3].